Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

NCT07400250 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG: Orelabrutinib
DRUG: Romiplostim N01

Sponsor

Peking Union Medical College Hospital